On October 1, 2009
Pfizer Email on “Negligible Evidence” for Neurontin as a Bipolar Drug Is Focus of Lawyers’ Tug-of-War
An email in the Neurontin litigation that Pfizer claims should be sealed shows former Pfizer vp/neuroscience Atul Pande telling a colleague that there is “negligible evidence” for the use of Neurontin in bipolar disorder and that the drug is “not a good anti-manic treatment.”
0 Comments